MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Danaher Corporation Revenue 2011-2026 | DHR
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Danaher Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24.6 B | 23.9 B | 23.9 B | 26.6 B | 24.8 B | 22.3 B | 17.9 B | 19.9 B | 18.3 B | 16.9 B | 20.6 B | 19.9 B | 19.1 B | 18.3 B | 16.1 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 26.6 B | 16.1 B | 20.9 B |
Quarterly Revenue Danaher Corporation
| 2025-Q1 | 2024-Q4 | 2024-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.74 B | - | 5.8 B | - | - | 7.75 B | 7.69 B | - | 7.23 B | 7.22 B | 6.86 B | - | 5.88 B | 5.3 B | 4.34 B | 4.87 B | 4.38 B | 4.44 B | 4.22 B | 5.36 B | 4.85 B | 4.98 B | 4.7 B | 5.09 B | 4.53 B | 4.51 B | 4.21 B | 4.58 B | 4.13 B | 4.24 B | 3.92 B | 4.32 B | 3.51 B | 4.96 B | 4.69 B | 5.22 B | 4.71 B | 4.96 B | 4.66 B | 5.04 B | 4.67 B | 4.74 B | 4.44 B | 4.98 B | 4.42 B | 4.55 B | 4.32 B | 4.72 B | 4.45 B | 3.64 B | 3.29 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.75 B | 3.29 B | 4.94 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Bioventus
BVS
|
568 M | $ 9.21 | 2.33 % | $ 614 M |  USA |
|
Biodesix
BDSX
|
71.3 M | $ 15.23 | 3.68 % | $ 1.97 B | USA |
 |
Biomerica
BMRA
|
5.31 M | $ 2.12 | -0.47 % | $ 4.87 M | USA |
 |
Fulgent Genetics
FLGT
|
283 M | $ 16.39 | 0.37 % | $ 496 M | USA |
 |
Guardant Health
GH
|
982 M | $ 84.87 | -0.11 % | $ 10.6 B | USA |
 |
ICON Public Limited Company
ICLR
|
5.48 B | $ 101.97 | 1.61 % | $ 8.41 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
4.3 B | $ 574.79 | -0.64 % | $ 46.2 B | USA |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | USA |
 |
Lantheus Holdings
LNTH
|
1.54 B | $ 75.1 | -0.83 % | $ 5.07 B | USA |
 |
Medpace Holdings
MEDP
|
2.53 B | $ 462.07 | 1.12 % | $ 13.3 B | USA |
 |
Myriad Genetics
MYGN
|
824 M | $ 4.78 | 2.47 % | $ 443 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
National Research Corporation
NRC
|
137 M | $ 17.3 | -1.2 % | $ 387 M | USA |
 |
Pacific Biosciences of California
PACB
|
160 M | $ 1.42 | 2.16 % | $ 426 M | USA |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
8.18 M | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
6.81 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M | USA |
 |
Precipio
PRPO
|
15.2 M | $ 26.8 | -0.48 % | $ 34.8 M | USA |
 |
Personalis
PSNL
|
84.6 M | $ 7.88 | 3.55 % | $ 467 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
RadNet
RDNT
|
2.04 B | $ 60.29 | -2.35 % | $ 4.53 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
 |
Charles River Laboratories International
CRL
|
4.02 B | $ 159.72 | 1.09 % | $ 7.92 B | USA |
 |
IQVIA Holdings
IQV
|
16.3 B | $ 164.83 | -1.28 % | $ 28.3 B | USA |
 |
Sotera Health Company
SHC
|
1.16 B | $ 13.87 | -0.07 % | $ 3.94 B | USA |
 |
Neuronetics
STIM
|
149 M | $ 1.48 | -7.81 % | $ 97.6 M | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
122 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
28.5 M | $ 1.23 | -15.76 % | $ 6.7 M | USA |
 |
Mettler-Toledo International
MTD
|
4.03 B | $ 1 264.62 | 2.06 % | $ 26.1 B |  Schweiz |
 |
Interpace Biosciences
IDXG
|
46.9 M | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
Illumina
ILMN
|
4.37 B | $ 125.89 | 1.7 % | $ 20 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.25 B | - | - | $ 10.6 B |  Niderland |
 |
Twist Bioscience Corporation
TWST
|
377 M | $ 46.28 | 4.0 % | $ 2.77 B | USA |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
14 B | $ 266.59 | 0.82 % | $ 22.2 B | USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K |  Israel |
 |
ENDRA Life Sciences
NDRA
|
6.17 K | $ 3.36 | -3.45 % | $ 1.8 M | USA |
 |
NeoGenomics
NEO
|
727 M | $ 8.03 | -0.86 % | $ 1.03 B | USA |
 |
Natera
NTRA
|
820 M | $ 196.14 | -1.97 % | $ 19.3 B | USA |
 |
Senseonics Holdings
SENS
|
35.3 M | $ 6.74 | 1.81 % | $ 281 M | USA |
 |
CareDx, Inc
CDNA
|
380 M | $ 17.84 | 1.59 % | $ 951 M | USA |